



PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-763-B (400.129))

In the Application of:

McSwiggen et al.

Serial No.: 10/667,271

Filing Date: September 16, 2003

For: RNA Interference Mediated Inhibition
Of Hepatitis C Virus (HCV) Gene
Expression Using Short Interfering
Nucleic Acid (siRNA)

Examiner: TBD

Group Art Unit: 1632

Confirmation No.: 8658

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:


- ☒ Information Disclosure Statement;
- ☒ Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/667,271 (Total 6 U.S. Patent Application Documents, 31 foreign patents and 427 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on 3-21 2005.

By :


Lisa M.W. Hillman

Reg. No. 43,673

McDONNELL BOEHNNEN HULBERT & BERGHOF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001
FACSIMILE: (312) 913-0002



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-763-B (400.129))**

In the Application of:)	
)	
McSwiggen et al.)	
)	Examiner: TBD
Serial No.: 10/667,271)	
)	Group Art Unit: 1632
Filing Date: September 16, 2003)	
)	Confirmation No.: 8658
For: RNA Interference Mediated Inhibition)	
Of Hepatitis C Virus (HCV) Gene)	
Expression Using Short Interfering)	
Nucleic Acid (siNA))	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. This application is a continuation-in-part of U.S. Serial No. 10/444,853 filed May 23, 2003, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 CFR §1.98(d), those references marked with an "*" have been previously cited and submitted to the Patent and Trademark Office with the prior applications and additional references are enclosed herein. All references cited are listed in the PTO-1449 form enclosed herewith.

The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the

national stage under 35 USC § 371 after June 30, 2003. In accordance with this waiver, cited U.S. patents and U.S. patent application publications are not enclosed.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: 3 - 21

2005 By:



Lisa M.W. Hillman
Reg. No. 43,673

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	09/301,511	04/28/99	Beigleman et al.			
	*	09/740,332	12/18/00	Blatt et al.			
	*	09/800,594	03/06/01	Usman and McSwiggen			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/417,012	04/16/03	McSwiggen et al.			
	*	10/422,704	04/24/03	McSwiggen et al.			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/652,791	08/29/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			
	*	10/727,780	12/03/03	Vaish et al.			
	*	10/757,803	01/14/04	McSwiggen et al.			
	*	10/780,447	02/13/04	Vargeese et al.			
	*	10/826,966	04/16/04	McSwiggen et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	60/082,404	04/20/98	Thompson et al.			
	1.	60/292,217	05/18/01	Adamic et al.			
	2.	60/306,883	07/20/01	Vargeese et al.			
	3.	60/311,865	08/13/01	Vargeese et al.			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	4.	60/386,782	06/06/02	Beigelman et al.			
	5.	60/401,104	08/05/02	McSwiggen et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			
	*	60/440,129	01/15/03	Beigelman et al.			
	*	60/543,480	02/10/04	Jadhavi et al.			
	*	US 2001/0007666	01/05/99	Hoffman et al.			
	*	US 2001/0007666	01/05/99	Hoffman et al.			07/12/01
	*	US 2002/0130430	12/29/00	Caster			09/19/02
	*	US 2002/0137210	08/09/01	Churikov			09/26/02

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	US 2003/0077829	04/30/02	MacLachlan			04/24/03
--	---	-----------------	----------	------------	--	--	----------

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,987,071	01/22/91	Cech et al.			
	*	5,108,921	04/28/92	Low et al.			
	*	5,138,045	08/11/92	Vargeese et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat			
	*	5,416,016	05/16/95	Low et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,670,633	09/23/97	Cook et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,741,679	04/21/98	George et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,831,071	11/03/98	Usman et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,854,038	12/29/98	Cech et al.			
	*	5,871,914	02/16/99	Nathan et al.			
	*	5,874,565	02/23/99	Rice et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,898,031	04/27/99	Crooke			
	*	5,902,880	05/11/99	Thompson et al.			
	*	5,968,909	10/19/99	Agrawal et al.			
	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/07/99	Adamic et al.			
	*	6,001,311	12/14/99	Brennan			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	6,005,087	12/21/99	Cook et al.			
	*	6,008,400	12/28/99	Scaringe et al.			
	*	6,054,576	04/25/00	Bellon et al.			
	*	6,107,094	08/22/00	Crooke			
	*	6,111,086	08/29/00	Scaringe et al.			
	*	6,117,657	09/12/00	Usman et al.			
	*	6,127,116	10/03/00	Rice et al.			
	*	6,146,886	11/14/00	Thompson			
	*	6,153,737	11/28/00	Manoharan et al.			
	*	6,162,909	12/19/00	Bellon et al.			
	*	6,168,778	01/02/01	Janjic et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,235,310	05/22/01	Wang et al.			
	*	6,235,886	05/22/01	Manoharan et al.			
	*	6,248,878	06/19/01	Adamic et al.			
	*	6,300,074	10/09/01	Gold			
	*	6,303,773	10/16/01	Bellon et al.			
	*	6,335,434	01/01/02	Guzaev et al.			
	*	6,350,934	02/26/02	Zwick et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/02	Usman et al.			
	*	6,395,492	05/28/02	Manoharan et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			
	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,506,559	06/14/03	Fire et al.			
	*	6,528,631	03/04/03	Cook et al.			
	*	6,586,524	07/01/03	Sagara			
	*	6,617,156	09/09/03	Doucette-Stam et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	2001240375 (Old Application No. 40375/01)	03/16/01	AU (Graham et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	2,359,180	08/03/00	CA (Kreutzer et al.)				
XVII-13	6.	0 360 257	02/28/90	EP (Hampel et al.)				
	*	1144623 B1	01/29/02	EP (Kreutzer et al.)				
	7.	88/09810	12/15/88	WO (Tullis et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	8.	90/12096	10/18/90	WO (Low et al.)				
	9.	90/14090	11/29/90	WO (Gillespie et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	04/30/92	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23569	11/25/93	WO (Draper et al.)				
	10.	94/01550	01/20/94	WO (Agrawal et al.)				
	*	94/02595	02/03/94	WO (Sullivan et al.)				
	*	95/06731	03/09/95	WO (Usman et al.)				
	11.	95/11304	04/27/95	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz et al.)				
	*	96/10390	04/11/96	WO (Ansell et al.)				
	*	96/10391	04/11/96	WO (Choi et al.)				
	*	96/10392	04/11/96	WO (Holland et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	12.	96/18736	06/20/96	WO (Beigelman et al.)				
	13.	96/22689	08/01/96	WO (Pyle et al.)				
	*	97/26270	07/24/97	WO (Beigelman et al.)				
	*	98/13526	04/02/98	WO (Woolf et al.)				
	14.	98/27104	06/25/98	WO (Breaker et al.)				
	15.	98/28317	07/02/98	WO (Matulic-Adamic et al)				
	16.	98/43993	10/08/98	WO (Breaker et al.)				
	17.	98/58058	12/23/98	WO (Ludwig & Sproat)				
	*	99/04819	02/04/99	WO (Klimuk)				
	*	99/05094	02/04/99	WO (Beigelman et al.)				
	*	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	*	99/14226	03/25/99	WO (Wengel et al.)				
	18.	99/16307	04/08/99	WO (Vierling)				
	19.	99/16871	04/08/99	WO (Eckstein et al.)				
	20.	99/17120	04/08/99	WO (Davis and Bishop)				
	21.	99/29842	06/17/99	WO (Sullenger et al.)				
	*	99/31262	06/24/99	WO (Barry et al.)				
	*	99/32619	07/01/99	WO (Fire et al.)				
	*	99/49029	09/30/99	WO (Graham et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	99/53050	10/21/99	WO (Waterhouse et al.)				
	*	99/54459	10/28/99	WO (Thompson et al.)				
	22.	99/55857	11/04/99	WO (Beigelman et al.)				
	*	99/61631	12/02/99	Heifetz et al.				
	23.	99/66063	12/23/99	WO (Manoharan et al.)				
	*	00/01846	01/13/00	WO (Plaetinck et al.)				
	24.	00/03683	01/27/00	WO (Boey et al.)				
	*	00/17369	03/30/00	WO (Gurney et al.)				
	25.	00/24931	05/04/00	WO (Nathan and Ellington)				
	26.	00/26226	05/11/00	WO (Breaker et al.)				
	*	00/44895	08/03/00	WO (Kreutzer et al.)				
	*	00/44914	08/03/00	WO (Li et al.)				
	27.	00/49035	08/24/00	WO (Sheen)				
	*	00/53722	09/14/00	WO (O'Hare and Normand)				
	*	00/63364	10/26/00	WO (Pachuk et al.)				
	*	00/66604	11/09/00	WO (Wengel et al.)				
	*	01/04313	01/18/01	WO (Satishchandran et al.)				
	*	01/29058	04/26/01	WO (Mello et al.)				
	*	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	01/38551	05/31/01	WO (Grossniklaus)				
	*	01/42443	06/14/01	WO (Churikov et al.)				
	*	01/49844	07/12/01	WO (Driscoll et al.)				
	*	01/53475	07/26/01	WO (Cogoni et al.)				
	*	01/68836	09/20/01	WO (Beach et al.)				
	*	01/70944	09/27/01	WO (Honer et al.)				
	*	01/70949	09/27/01	WO (Graham et al.)				
	*	01/72774	10/04/01	WO (Deak et al.)				
	*	01/75164	10/11/01	WO (Tuschl et al.)				
	*	01/92513	12/06/01	WO (Arndt et al.)				
	28.	01/96584	12/20/01	WO (Mushegian et al.)				
	*	02/22636	03/21/02	WO (Bennett et al.)				
	*	02/38805	05/16/02	WO (Echeverri et al.)				
	*	02/44321	06/06/02	WO (Tuschl et al.)				
	*	02/055692	07/18/02	WO (Kreutzer et al.)				
	*	02/055693	07/18/02	WO (Kreutzer et al.)				
	29.	02/081494 (PCT/US02/09187)	03/26/02	WO (Beigelman et al.)				
	30.	02/087541	11/07/02	WO (MacLachlan)				
	*	02/094185 (PCT/US02/15876)	01/28/02	WO (Beigelman et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	31.	03/024420	03/27/03	WO (Ahlheim et al.)				
	32.	03/046185	06/05/03	WO (Wang et al.)				
	33.	03/047518	06/12/03	WO (Wang et al.)				
	*	03/064625	08/07/03	WO (Woolf et al.)				
	*	03/064626	08/07/03	WO (Woolf et al.)				
	34.	03/070750 (PCT/US03/05043)	08/28/03	WO (McSwiggen et al.)				
	*	03/070918 (PCT/US03/05346)	08/28/03	WO (McSwiggen et al.)				
	*	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				
	*	04/013280	02/12/04	WO (Davidson et al.)				
	35.	PCT/US04/13456	04/30/04	Vargeese et al.				
	36.	PCT/US04/16390	05/24/04	McSwiggen et al.				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	37.	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <u>Science</u> 271:1410-1413 (1996)						
	*	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <u>Current Medicinal Chemistry</u> , 8, 1189-1212 (2001)						
	*	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <u>Trends Cell Biol.</u> 2:139-144 (1992)						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
	*	Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <u>Science</u> 297:1818-1819 (2002)
	38.	Alter, "Chronic Consequences of Non-A, Non-B Hepatitis," <i>Current Perspectives in Hepatology</i> , pp. 83-89 (1989)
	*	Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <u>Nucleic Acids Research</u> 19:2499 (1991)
	39.	Antopolsky et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," <u>Bioconjugate Chem.</u> 10:598-606 (1999)
	40.	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <u>Science</u> 279:377-380 (1998)
	*	Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <u>Cell</u> 22:611-620 (1980)
	*	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	41.	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
	*	Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <u>Brain Research</u> 784:305-315 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	*	Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	*	Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," <i>Science</i> 261:1411-1418 (1993)
	*	Basi et al., "Antagonistic Effects of β -Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on β -Amyloid Peptide Production in Cells*," <i>The Journal of Biological Chemistry</i> , 278, 31512-31520 (2003)
	*	Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
	*	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	*	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	*	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <i>Science</i> 257:635-641 (1992)
	*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
	*	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
	*	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)
	42.	Bennett et al., "Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides," <i>Mol. Pharmacology</i> 41:1023-1033 (1992)
	*	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
	43.	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <i>EMBO J.</i> 12:2567-2574 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(Use several sheets if necessary)</p>		02-763-B (400/129)	10/667,271
		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

44.	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <i>Genes & Development</i> 6:129-134 (1992)
*	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
45.	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <i>Biochemistry</i> 35:648-658 (1996)
46.	Blight et al., "Efficient Initiation of HCV RNA Replication in Cell Culture," <i>Science</i> 290:1972-1974 (2000)
*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
*	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," <i>Nucleic Acids Research</i> 22:4681-4688 (1994)
47.	Bonora et al., "Biological Properties of Antisense Oligonucleotides Conjugated to Different High-Molecular Mass Poly(ethylen glycols)," <i>Nucleosides & Nucleotides</i> 18:1723-1725 (1999)
48.	Bonora et al., "Synthesis and Characterization of High-Molecular Mass Polyethylene Glycol-Conjugated Oligonucleotides," <i>Bioconjugate Chem.</i> 8:793-797 (1997)
49.	Borden, "Interferons—Expanding Therapeutic Roles," <i>The New England Journal of Medicine</i> 326(22):1491-1493 (1992)
50.	Brand, "Topical and transdermal delivery of antisense oligonucleotides," <i>Curr. Opin. Mol. Ther.</i> , 3(3):244-248 (2001) [ABSTRACT ONLY]
*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

51.	Breaker et al., "A DNA enzyme with Mg ² -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
*	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
52.	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
*	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>Neurosurg. Focus</i> 3(5):Article 4 (1997)
*	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>J Neurosurg</i> 88:734-742 (1998)
*	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
*	Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Cene Expression and Viral Replication," <i>Journal of Virology</i> , 5845-5851 (1996)
*	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)
*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
*	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

	*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
	53.	Cebon et al., "New DNA Modification Strategies Involving Oxime Formation," <u>Aust. J. Chem.</u> 53:333-339 (2000)
	54.	Cech, "Ribozymes and Their Medical Implications," <u>JAMA</u> 260:3030-3034 (1988)
	55.	Chaloin et al., "Design of Carrier Peptide-Oligonucleotide Conjugates With Rapid Membrane Translocation and Nuclear Localization Properties," <u>BBRC</u> 243:601-608 (1998)
	56.	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <u>Nucleic Acids Research</u> 23(20):4092-4096 (1995)
	57.	Chebath & Revel, "The 2-5 A System: 2-5 A Synthetases, Isospecies and Functions," <i>Interferon: Principles and Medical Applications</i> pp225-236 (1992)
	58.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
	*	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <u>RNA</u> , 9:1034-1048 (2003)
	*	Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector in vitro," <u>Bull. Korean Chem. Soc.</u> , 22, 46-52 (2001)
	59.	Choo et al., "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome," <u>Science</u> 244:359-362 (1989)
	60.	Chowrira et al., " <i>In Vitro</i> and <i>in Vivo</i> Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
	61.	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <u>Nature</u> 354:320-322 (1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	*	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," <i>Neuroscience Letters</i> 257:135-138 (1998)
	*	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
	*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
	62.	Cole et al., "Activation of RNase L by 2',5'-Oligoadenylates," <i>The Journal of Biological Chemistry</i> , 272:31, 19187-19192 (1997)
	63.	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <i>Biochemistry</i> 32:2795-2799 (1993)
	*	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	*	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999)
	64.	Costa-Mattioli et al., "La Autoantigen Is Necessary for Optimal Function of the Poliovirus and Hepatitis C Virus Internal Ribosome Entry Site In Vivo and In Vitro," <i>Molecular and Cellular Biology</i> , 24(15):6861-6870 (2004)
	65.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
	66.	Cribier et al., " <i>In vitro</i> infection of peripheral blood mononuclear cells by hepatitis C virus," <i>Journal of General Virology</i> 76:2485-2491 (1995)
	67.	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

68.	Crooke, "Antisense Therapeutics," <u>Biotechnology and Genetic Engineering Reviews</u> 15:121-157 (1998)
69.	Crooke, "Progress in Antisense Technology: The End of the Beginning," <u>Methods in Enzymology</u> 313:3-45 (1999)
*	d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," <u>Molecular Brain Research</u> 55:151-164 (1998)
70.	D'Amico et al., "Survival and Prognostic Indicators in Compensated and Decompensated Cirrhosis," <u>Digestive Diseases and Sciences</u> 31(5):468-475 (1986)
71.	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <u>J. Mol. Biol.</u> 256:31-49 (1996)
72.	Dash et al., "Transfection of HepG2 Cells with Infectious Hepatitis C Virus Genome," <u>American Journal of Pathology</u> 151(2):363-373 (1997)
*	Database CAPLUS on STN, AN:1992:230597, Segarra et al., "Molecular Characterization of the Enterococcus Faecalis Cytolysin Activator", <u>Infection and Immunity</u> , 1991, Vo. 59, No. 4, pages 1239-46
73.	Davis and Lim, "Current Status of Interferon Therapy for Chronic Hepatitis C: A Hepatologist's Perspective," <u>Infectious Agents and Disease</u> 2:150-154 (1993)
74.	Davis et al., "Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa," <u>The New England Journal of Medicine</u> 321(22):1501-1506 (1989)
75.	Defrancq and Lhomme, "Use of an Aminooxy Linker for the Functionalization of Oligodeoxyribonucleotides," <u>Bioorganic & Medicinal Chem. Lett.</u> 11:931-933 (2001)
76.	Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <u>Nature Biotechnology</u> 15:751-753 (1997)
*	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <u>The Journal of Biological Chemistry</u> , 274, 19087-19094 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

77.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
*	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," <u>Journal of Endocrinology</u> 157:169-175 (1998)
*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
78.	Dusheiko et al., "Sequence variability of hepatitis C virus and its clinical relevance," <u>Journal of Viral Hepatitis</u> 1:3-15 (1994)
79.	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <u>Proc. Natl. Acad. Sci. USA</u> 89:504-508 (1992)
*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)
*	Edbauer et al., Resenilin and nicastrin regulate each other and determine amyloid β -peptide production via complex formation," <u>PNAS</u> , 99, 8666-8671 (2002)
80.	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <u>Nature</u> 365:566-568 (1993)
*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001)
*	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <u>The EMBO Journal</u> 20:6877-6888 (2001)
*	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <u>Genes and Development</u> 15:188-200 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.		
(Use several sheets if necessary)		Filing Date: September 16, 2003	Group: 1632	

	*	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
81.		Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
	*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
	*	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and In Vivo, Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <u>Antisense and Nucleic Acid Drug Dev.</u> 10:469-478 (2000)
	*	Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <u>The Journal of Gene Medicine</u> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
82.		Farci et al., "A Long-Term Study of Hepatitis C Virus Replication in Non-A, Non-B Hepatitis," <u>The New England Journal of Medicine</u> 325(2):98-104 (1991)
83.		Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <u>Gene</u> 82:53-61 (1989)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)
	*	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <u>Biochimica et Biophysica Acta</u> 1329:345-356 (1997)
84.		Findeis, "Stepwise Synthesis of a GalNAc-containing Cluster Glycoside Ligand of the Asialoglycoprotein Receptor," <u>Int. J. Peptide Protein Res.</u> 43:477-485 (1994)
	*	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <u>Nature</u> 391:806-811(1998)
	*	Fire, "RNA-triggered Gene Silencing," <u>TIG</u> 15:358-363(1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

85.	Fish et al., "The Role of Three Domains in the Biological Activity of Human Interferon- α ," <u>Journal of Interferon Research</u> 9:97-114 (1989)
86.	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
87.	Fox, "Targeting DNA with Triplexes," <u>Current Medicinal Chemistry</u> 7:17-37 (2000)
*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986) [sometimes referred to as Frier]
*	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <u>Bioconjugate Chem.</u> , 14, 840-847 (2003)
*	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <u>Nucleic Acids Research Supplement</u> , 251-252 (2002)
88.	Galun et al., "Hepatitis C Virus Viremia in SCID→BNX Mouse Chimera," <u>The Journal of Infectious Diseases</u> 172:25-30 (1995)
89.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
90.	GenBank Accession No. D84263.1
91.	GenBank Accession No. AB016785.1
*	GenBank Accession No. AB020693
92.	GenBank Accession No. AB030907.1
93.	GenBank Accession No. AB031663.1
94.	GenBank Accession No. AB047639.1
95.	GenBank Accession No. AB047640.1
96.	GenBank Accession No. AB047641.1
97.	GenBank Accession No. AB047642.1
98.	GenBank Accession No. AB047643.1
99.	GenBank Accession No. AB047644.1

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

100.	GenBank Accession No. AB047645.1
101.	GenBank Accession No. AB049087.1
102.	GenBank Accession No. AB049088.1
103.	GenBank Accession No. AB049089.1
104.	GenBank Accession No. AB049090.1
105.	GenBank Accession No. AB049091.1
106.	GenBank Accession No. AB049092.1
107.	GenBank Accession No. AB049093.1
108.	GenBank Accession No. AB049094.1
109.	GenBank Accession No. AB049095.1
110.	GenBank Accession No. AB049096.1
111.	GenBank Accession No. AB049097.1
112.	GenBank Accession No. AB049098.1
113.	GenBank Accession No. AB049099.1
114.	GenBank Accession No. AB049100.1
115.	GenBank Accession No. AB049101.1
116.	GenBank Accession No. AF082503.1
117.	GenBank Accession No. AF009606.1
118.	GenBank Accession No. AF011751.1
119.	GenBank Accession No. AF011752.1
120.	GenBank Accession No. AF011753.1
*	GenBank Accession No. AF037412
121.	GenBank Accession No. AF046866.1
122.	GenBank Accession No. AF054247.1
123.	GenBank Accession No. AF054248.1
124.	GenBank Accession No. AF054249.1
125.	GenBank Accession No. AF054250.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

126.	GenBank Accession No. AF054251.1
127.	GenBank Accession No. AF054252.1
128.	GenBank Accession No. AF054253.1
129.	GenBank Accession No. AF054254.1
130.	GenBank Accession No. AF054255.1
131.	GenBank Accession No. AF054256.1
132.	GenBank Accession No. AF054257.1
133.	GenBank Accession No. AF054258.1
134.	GenBank Accession No. AF054259.1
*	GenBank Accession No. AF063658
135.	GenBank Accession No. AF064490.1
136.	GenBank Accession No. AF082503.1
*	GenBank Accession No. AF100308.1
137.	GenBank Accession No. AF139594.1
138.	GenBank Accession No. AF165045.1
139.	GenBank Accession No. AF165046.1
140.	GenBank Accession No. AF165047.1
141.	GenBank Accession No. AF165048.1
142.	GenBank Accession No. AF165049.1
143.	GenBank Accession No. AF165050.1
144.	GenBank Accession No. AF165051.1
145.	GenBank Accession No. AF165052.1
146.	GenBank Accession No. AF165053.1
147.	GenBank Accession No. AF165054.1
148.	GenBank Accession No. AF165055.1
149.	GenBank Accession No. AF165056.1
150.	GenBank Accession No. AF165057.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

151.	GenBank Accession No. AF165058.1
152.	GenBank Accession No. AF165059.1
153.	GenBank Accession No. AF165060.1
154.	GenBank Accession No. AF165061.1
155.	GenBank Accession No. AF165062.1
156.	GenBank Accession No. AF165063.1
157.	GenBank Accession No. AF165064.1
158.	GenBank Accession No. AF169002.1
159.	GenBank Accession No. AF169003.1
160.	GenBank Accession No. AF169004.1
161.	GenBank Accession No. AF169005.1
162.	GenBank Accession No. AF176573.1
163.	GenBank Accession No. AF177036.1
164.	GenBank Accession No. AF177037.1
165.	GenBank Accession No. AF177038.1
166.	GenBank Accession No. AF177039.1
167.	GenBank Accession No. AF177040.1
168.	GenBank Accession No. AF207752.1
169.	GenBank Accession No. AF207753.1
170.	GenBank Accession No. AF207754.1
171.	GenBank Accession No. AF207755.1
172.	GenBank Accession No. AF207756.1
173.	GenBank Accession No. AF207757.1
174.	GenBank Accession No. AF207758.1
175.	GenBank Accession No. AF207759.1
176.	GenBank Accession No. AF207760.1
177.	GenBank Accession No. AF207761.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

178.	GenBank Accession No. AF207762.1
179.	GenBank Accession No. AF207763.1
180.	GenBank Accession No. AF207764.1
181.	GenBank Accession No. AF207765.1
182.	GenBank Accession No. AF207766.1
183.	GenBank Accession No. AF207767.1
184.	GenBank Accession No. AF207768.1
185.	GenBank Accession No. AF207769.1
186.	GenBank Accession No. AF207770.1
187.	GenBank Accession No. AF207771.1
188.	GenBank Accession No. AF207772.1
189.	GenBank Accession No. AF207773.1
190.	GenBank Accession No. AF207774.1
191.	GenBank Accession No. AF208024.1
192.	GenBank Accession No. AF238481.1
193.	GenBank Accession No. AF238482.1
194.	GenBank Accession No. AF238483.1
195.	GenBank Accession No. AF238484.1
196.	GenBank Accession No. AF238485.1
197.	GenBank Accession No. AF238486.1
198.	GenBank Accession No. AF256223
199.	GenBank Accession No. AF271632.1
200.	GenBank Accession No. AF290978.1
201.	GenBank Accession No. AF313916.1
202.	GenBank Accession No. AF333324.1
203.	GenBank Accession No. AF356827.1
204.	GenBank Accession No. AF483269.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

205.	GenBank Accession No. AF511948.1
206.	GenBank Accession No. AF511949.1
207.	GenBank Accession No. AF511950.1
208.	GenBank Accession No. AJ000009.1
209.	GenBank Accession No. AJ132996.1
210.	GenBank Accession No. AJ132997.1
211.	GenBank Accession No. AJ238799.1
212.	GenBank Accession No. AJ238800.1
213.	GenBank Accession No. AJ242651.1
214.	GenBank Accession No. AJ242653.1
215.	GenBank Accession No. AJ278830.1
*	GenBank Accession No. AJ430458
216.	GenBank Accession No. AX036253.1
217.	GenBank Accession No. AX036256.1
218.	GenBank Accession No. AX057086.1
219.	GenBank Accession No. AX057088.1
220.	GenBank Accession No. AX057090.1
221.	GenBank Accession No. AX057092.1
222.	GenBank Accession No. AX057094.1
223.	GenBank Accession No. AX057317.1
224.	GenBank Accession No. AX057395.1
225.	GenBank Accession No. AX100563.1
226.	GenBank Accession No. AY045702.1
227.	GenBank Accession No. AY051292.1
*	GenBank Accession No. D00239
228.	GenBank Accession No. D00944.1
229.	GenBank Accession No. D10749.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

230.	GenBank Accession No. D10750.1
231.	GenBank Accession No. D10934.1
232.	GenBank Accession No. D10988.1
*	GenBank Accession No. D11168
233.	GenBank Accession No. D11355.1
234.	GenBank Accession No. D13558.1
235.	GenBank Accession No. D14484.1
236.	GenBank Accession No. D14853.1
237.	GenBank Accession No. D17763.1
238.	GenBank Accession No. D28917.1
239.	GenBank Accession No. D30613.1
240.	GenBank Accession No. D45172.1
241.	GenBank Accession No. D49374.1
242.	GenBank Accession No. D50409.1
243.	GenBank Accession No. D50480.1
244.	GenBank Accession No. D50481.1
245.	GenBank Accession No. D50482.1
*	GenBank Accession No. D50483.1
246.	GenBank Accession No. D50484.1
247.	GenBank Accession No. D50485.1
248.	GenBank Accession No. D63821.1
249.	GenBank Accession No. D63822.1
250.	GenBank Accession No. D63857.1
251.	GenBank Accession No. D84262.1
252.	GenBank Accession No. D84264.1
253.	GenBank Accession No. D84265.1
254.	GenBank Accession No. D85516.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	255.	GenBank Accession No. D89815.1
	256.	GenBank Accession No. D89872.1
	257.	GenBank Accession No. D90208.1
	258.	GenBank Accession No. E03766.1
	259.	GenBank Accession No. E04420.1
	260.	GenBank Accession No. E05027.1
	261.	GenBank Accession No. E06261.1
	262.	GenBank Accession No. E06457.1
	263.	GenBank Accession No. E07579.1
	264.	GenBank Accession No. E08263.1
	265.	GenBank Accession No. E08264.1
	266.	GenBank Accession No. E08399.1
	267.	GenBank Accession No. E08443.1
	268.	GenBank Accession No. E08461.1
	269.	GenBank Accession No. E10839.1
	270.	GenBank Accession No. E66593.1
	*	GenBank Accession No. K02121
	271.	GenBank Accession No. L02836.1
	*	GenBank Accession No. L24917
	*	GenBank Accession No. L38318
	*	GenBank Accession No. M16248
	*	GenBank Accession No. M31724
	272.	GenBank Accession No. M58335.1
	273.	GenBank Accession No. M62321.1
	274.	GenBank Accession No. M67463.1
	275.	GenBank Accession No. M84754.1
	276.	GenBank Accession No. M96362.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

	*	GenBank Accession No. NC_001345
	*	GenBank Accession No. NC_001347
	*	GenBank Accession No. NC_001353
277.		GenBank Accession No. NC_001433.1
	*	GenBank Accession No. NC_001563
	*	GenBank Accession No. NC_001781
278.		Genbank Accession No. NC_004718
279.		GenBank Accession No. NM_000043
280.		GenBank Accession No. NM_000639
	*	GenBank Accession No. NM_001285
	*	GenBank Accession No. NM_001982
	*	GenBank Accession No. NM_002592.1
	*	GenBank Accession No. NM_002667
	*	GenBank Accession No. NM_002737
281.		GenBank Accession No. NM_003142
	*	GenBank Accession No. NM_003219
	*	Genbank Accession No. NM_003376.1
	*	GenBank Accession No. NM_004283
	*	GenBank Accession No. NM_004448
	*	GenBank Accession No. NM_005228
	*	GenBank Accession No. NM_005235
282.		GenBank Accession No. NM_006874.1
283.		GenBank Accession No. NM_031991.1
284.		GenBank Accession No. S62220.1
	*	GenBank Accession No. S82227
285.		GenBank Accession No. U01214.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-763-B
(400/129)

Serial No.

10/667,271

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 16, 2003

Group:

1632

286.	GenBank Accession No. U16362.1
287.	GenBank Accession No. U45476.1
*	GenBank Accession No. U51188
*	GenBank Accession No. U86046
288.	GenBank Accession No. U89019.1
*	GenBank Accession No. X01087
*	GenBank Accession No. X02316
*	GenBank Accession No. X07203
*	GenBank Accession No. X60667
289.	GenBank Accession No. X61596.1
290.	GenBank Accession No. X76918.1
291.	GenBank Accession No. XM_002661.7
*	GenBank Accession No. XM_015620
292.	GenBank Accession No. XM_018021.2
*	GenBank Accession No. XM_033884
293.	GenBank Accession No. XM_042972.3
*	GenBank Accession No. XM_067723
294.	GenBank Accession No. Y11604.1
295.	GenBank Accession No. Y12083.1
296.	GenBank Accession No. Y13184.1
*	Ghirnikar et al., "Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides," <i>Neuroscience Letters</i> 247:21-24 (1998)
*	Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
*	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(Use several sheets if necessary)		
Applicant:				
McSwiggen et al.				
Filing Date:		Group:		
September 16, 2003		1632		

297.	Godwin et al., "The Synthesis of Biologically Active Pteroylolo- γ -L-Glutamates (Folic Acid Conjugates)," <u>The Journal of Biological Chemistry</u> 247:2266-2271 (1972)
*	Gold et al., "Diversity of Oligonucleotide Functions," <u>Annu. Rev. Biochem.</u> 64:763-797 (1995)
*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <u>Neuroscience</u> 76:1153-1158 (1997)
*	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <u>Bioconjugate Chem.</u> , 10, 1068-1074 (1999)
298.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
*	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <u>Diabetologia</u> 36:282-291 (1993)
299.	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
300.	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <u>Chemistry & Biology</u> 2:761-770 (1995)
301.	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <u>Cell</u> 35:849-857 (1983)
302.	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <u>EMBO J.</u> 14:368-376 (1995)
303.	Habus et al., "A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates," <u>Bioconjugate Chem.</u> 9:283-291 (1998)
*	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <u>Science</u> 297:2232-2237 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.		
(Use several sheets if necessary)		Filing Date: September 16, 2003	Group: 1632	

	*	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999))
	304.	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <i>Antisense & Nucleic Acid Drug Development</i> 9:25-31 (1999)
	*	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
	305.	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <i>Biochemistry</i> 28:4929-4933 (1989)
	306.	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <i>Nucleic Acids Research</i> 18:299-304 (1990)
	*	Haniu et al., "Characterization of Alzheimer's β -Secretase Protein BACE," <i>The Journal of Biological Chemistry</i> , 275, 21099-21106 (2000)
	307.	Harada et al., "Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA," <i>Journal of General Virology</i> 76:1215-1221 (1995)
	*	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
	308.	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <i>RNA</i> 1:210-218 (1995)
	*	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 285:920-928 (1998)
	309.	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," <i>Gene</i> 82:43-52 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

310.	Hayashi et al., " <i>In Vivo</i> Transfection of Rat Liver with Hepatitis C Virus cDNA Using Cationic Liposome-Mediated Gene Delivery," <i>HCD Gene Delivery</i> pp143-149 (1995)
311.	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <i>Biochemistry</i> 34:15813-15828 (1995)
*	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)
312.	Herrmann et al., "Comparative analysis of adenoviral transgene delivery via tail or portal vein into rat liver," <i>Arch Virol</i> 149:1611-1617 (2004)
313.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <i>Biochemistry</i> 29:10159-10171 (1990)
314.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <i>Biochemistry</i> 29:10172-10180 (1990)
315.	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <i>Biochemistry</i> 33:3374-3385 (1994)
316.	Hertel et al., "Numbering System for the Hammerhead," <i>Nucleic Acids Research</i> 20:3252 (1992)
317.	Hiramatsu et al., "HCV cDNA transfection to HepG2 cells," <i>Journal of Viral Hepatitis</i> 4:61-67 (1997) [sometimes referred to as Haramatsu]
*	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)
318.	Hong et al., <i>J. Pharm. Pharmacol.</i> , 54, 51-58 (2003)
319.	Hoofnagle et al., "The treatment of chronic viral hepatitis," <i>The New England Journal of Medicine</i> 336(5):347-356 (1997)
320.	Horisberger, "MX Protein: Function and Mechanism of Action," <i>Interferon: Principles and Medical Applications</i> pp215-224 (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	321.	Houghton et al., "Molecular Biology of the Hepatitis C Viruses: Implications for Diagnosis, Development and Control of Viral Disease," <u>Hepatology</u> 14(2):381-388 (1991)
	322.	Hudson et al., "Cellular Delivery of Hammerhead Ribozymes Conjugated to a Transferrin Receptor Antibody," <u>Int'l Jour. of Pharmaceutics</u> 182:49-58 (1999)
	*	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <u>VCH</u> , 331-417
	*	Hussain et al., "Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase," <u>Molecular and Cellular Neuroscience</u> , 14, 419-427 (1999)
	*	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <u>Science</u> 297:2056-2060 (2002)
	*	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <u>Science</u> 293:834-838 (2001)
	323.	Iacovacci et al., "Molecular Characterization and Dynamics of Hepatitis C Virus Replication in Human Fetal Hepatocytes Infected <i>In Vitro</i> ," <u>Hepatology</u> 26(5):1328-1337 (1997)
	324.	Iacovacci et al., "Quantitation of hepatitis C virus RNA production in two human bone marrow-derived B-cell lines infected <i>in vitro</i> ," <u>Institut Pasteur/Elsevier</u> 148:147-151 (1997)
	*	International Search Report for PCT/US03/04710 mailed November 18, 2003
	*	International Search Report for PCT/US03/05028 mailed October 17, 2003
	*	International Search Report for PCT/US03/05346 mailed October 17, 2003
	*	International Search Report mailed November 19, 2003 for PCT/US03/18911
	*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

325.	Ito et al., "Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus," <u>Journal of General Virology</u> 77:1043-1054 (1996)
326.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)
327.	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," <u>Journal of Biological Chemistry</u> 271:29107-29112 (1996)
*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993) (sometimes mistakenly referred to as Jscke)
328.	Jaschke et al., "Synthesis and Properties of Oligodeoxyribonucleotide-polyethylene Glycol Conjugates," <u>Nucleic Acids Research</u> 22:4810-4817 (1994)
329.	Jaschke, "Oligonucleotide-Poly(ethylene glycol) Conjugates: Synthesis, Properties, and Application," <u>American Chemical Society</u> 680:265-283 (1997)
*	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999)
*	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <u>Science</u> 297:2215-2218 (2002)
330.	Johnson et al., "How Interferons Fight Disease," <u>Scientific American</u> , pp. 68-75 (May 1994)
*	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
331.	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes & Development</u> 7:130-138 (1993)
*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
*	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	332.	Kanikkannan, "Iontophoresis-Based Transdermal Delivery Systems, <i>Biodrugs</i> , 16(5):339-347 (2002)
	*	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABAA Receptor $\gamma 2$ Subunit," <i>Euro. Jour. of Pharmacology</i> 340:153-160 (1997)
	*	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <i>Tetrahedron Letters</i> 39:1131-1134 (1998)
	333.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <i>Antisense Research & Development</i> 2:3-15 (1992)
	334.	Kato et al., "Molecular structure of the Japanese hepatitis C viral genome," <i>Federation of European Biochemical Societies</i> 280(2):325-328 (1991)
	335.	Kato et al., "Susceptibility of Human T-Lymphotropic Virus Type I Infected Cell Line MT-2 Hepatitis C Virus Infection ¹ ," <i>Biochemical and Biophysical Research Communications</i> 206(3):863-869 (1995)
	336.	Kawamura et al., "Transgenic Expression of Hepatitis C Virus Structural Proteins in the Mouse," <i>Hepatology</i> 25(4):1014-1021 (1997)
	*	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> 362:841-844 (1993)
	337.	Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK_a ," <i>Biochemistry</i> 35:1560-1570 (1996)
	*	Koch et al., "Vascular Endothelial Growth Factor," <i>Journal of Immunology</i> 152:4149-4156 (1994)
	338.	Koike et al., "Expression of hepatitis C virus envelope proteins in transgenic mice," <i>Journal of General Virology</i> 76:3031-3038 (1995)
	*	Koike et al., "Thimet Oligopeptidase Cleaves the Full-Length Alzheimer Amyloid Precursor Protein at a β -Secretase Cleavage Site in COS Cells," <i>J. Biochem.</i> , 126, 235-242 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

339.	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule," <i>Nucleic Acids Research</i> , 26(18):4116-4120 (1998).
*	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <i>Blood</i> 91:852-862 (1998)
*	Kumar and Ellington, "Artificial evolution and natural ribozymes," <i>FASEB J.</i> 9:1183-1195 (1995)
*	Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," <i>Medline (Pharm Res.)</i> 19(6): 810-817 (6/1/2002)
*	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
*	Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," <i>Current Opinion in Chem. Biol.</i> 4:669-677 (2000)
*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
*	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
*	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)
*	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glyconjugates J.</i> 4:317-328 (1987)
*	Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," <i>Nucleic Acids Research</i> 29:1565-1573 (2001)
340.	Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," <i>Nature Biotechnology</i> 19:500-505 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

341.	Lee et al., "Stimulation of Natural Killer Cell Activity and Inhibition of Proliferation of Various Leukemic Cells by Purified Human Leukocyte Interferon Subtypes," <u>Cancer Research</u> 42:1312-1316 (1982)
342.	Leifer et al., "Heterogeneity in the Human Response to Immunostimulatory CpG Oligodeoxynucleotides," <u>Journal of Immunotherapy</u> , 26(4):313-319 (2003)
343.	Leinbach et al., "Substrate Specificity of the NS3 Serine Proteinase of Hepatitis C Virus as Determined by Mutagenesis at the NS3/NS4A Junction," <u>Virology</u> 204:163-169 (1994)
*	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <u>Biochemical and Biophysical Research Communications</u> , 295, 744-748 (2002)
*	Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," <u>Science</u> , 296, 1673-1676 (2002)
*	Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <u>Journal of Ocular Pharmacology</u> 10:273-281 (1994)
344.	Leventhal et al., "Long-Term Response of Recurrent Respiratory Papillomatosis to Treatment with Lymphoblastoid Interferon Alfa-n1," <u>The New England Journal of Medicine</u> 325(9):613-617 (1991)
345.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <u>EMBO J.</u> 11:4411-4418 (1992)
346.	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," <u>Nucleic Acids Research</u> 24:835-842 (1996)
347.	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <u>Biochemistry</u> 34:14394-14399 (1995)
348.	Li et al., "Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing," <u>PNAS</u> , 101:5, 1350-1355 (2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

349.	Liang et al., "Viral Pathogenesis of Hepatocellular Carcinoma in the United States," <i>Hepatology</i> 18(6):1326-1333 (1993)
*	Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," <i>Journal of General Virology</i> , 84, 975-980 (2003)
350.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)
*	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
*	Lin et al., "Human aspartic protease memapsin 2 cleaves the β -secretase siet of β -amyloid precursor protein," <i>PNAS</i> , 97, 1456-1460 (2000)
*	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
351.	Lindgren et al., "Translocation Properties of Novel Cell Penetrating Transportan and Penetratin Analogues," <i>Bioconjugate Chem.</i> 11:619-626 (2000)
352.	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <i>J. Mol. Biol.</i> 235:1206-1217 (1994)
353.	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
*	Liu et al., "Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA," <i>Gene Therapy</i> , 6, 1258-1266 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	354.	Liu et al., "Poly(cationic lipid)-mediated <i>in vivo</i> gene delivery to mouse liver," <i>Gene Therapy</i> , 10:180-187 (2003)
	*	Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)
	355.	Blight et al., "Efficient Initiation of HCV RNA Replication in Cell Culture," <i>Science</i> 290:1972-1974 (2000)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)
	*	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," <i>Leukemia Research</i> 20:925-930 (1996)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	356.	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," <i>Biochemistry</i> 29:8820-8826 (1990)
	357.	Marcellin et al., "Recombinant Human α -Interferon in Patients with Chronic Non-A, Non-B Hepatitis: A Multicenter Randomized Controlled Trial from France," <i>Hepatology</i> 13(3):393-397 (1991)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
	358.	Matsuno et al., "Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis," <i>Gene Therapy</i> , 10:1559-1566 (2003)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

	*	Matulic-Adamic et al., "Functionalized Nucleoside 5'-triphosphates for In Vitro Selection of New Catalytic Ribonucleic Acids," <u>Bioorganic & Medicinal Chemistry Letters</u> 10:1299-1302 (2000)
	*	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <u>Molecular Membrane Biology</u> 16:129-140 (1999)
	359.	McCaffrey et al., "RNA interference in adult mice," <u>Nature</u> , 418, 38-39 (2002)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	360.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)
	361.	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <u>RNA</u> 2:395-403 (1996)
	*	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <u>RNA</u> 8:842-850 (2002)
	*	Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," <u>American Chemical Society</u> , pp. 24-39 (1994)
	362.	Michel and Westhof, "Slippery substrates," <u>Nat. Struct. Biol.</u> 1:5-7 (1994)
	363.	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461 (1995)
	364.	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)
	365.	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <u>Nature Biotechnology</u> 15:537-541 (1997)
	366.	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," <u>Nature Biotechnology</u> 19:497-500 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

367.	Mizuno et al., "Virion-like Structures in HeLa G Cells Transfected with the Full-Length Sequence of the Hepatitis C Virus Genome," <u>Gastroenterology</u> 109:1933-1940 (1995)
368.	Mizutani et al., "Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2," <u>Journal of Virology</u> 70(10):7219-7223 (1996)
369.	Mizutani et al., "Long-Term Human T-Cell Culture System Supporting Hepatitis C Virus Replication," <u>Biochemical and Biophysical Research Communications</u> 227:822-826 (1996)
370.	Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the <i>Tetrahymena</i> ribozyme," <u>Nature</u> 370:147-150 (1994)
*	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
*	Mori et al., <u>J. Cellular Physiology</u> , 188, 253-263 (2001)
371.	Moriya et al., "Hepatitis C virus core protein induces hepatic steatosis in transgenic mice," <u>Journal of General Virology</u> 78:1527-1531 (1997) [mistakenly referred to as Mariya]
372.	Morris et al., "A New Peptide Vector for Efficient Delivery of Oligonucleotides into Mammalian Cells," <u>Nucleic Acids Research</u> 25:2730-2736 (1997)
373.	Murao et al., "Targeting Efficiency of Galactosylated Liposomes to Hepatocytes <i>in Vivo</i> : Effect of Lipid Composition," <u>Pharmaceutical Research</u> , 19(12):1808-1814 (2002)
374.	Nakajima et al., "Characterization of Long-Term Cultures of Hepatitis C Virus," <u>Journal of Virology</u> 70(5):3325-3329 (1996)
*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)
375.	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

376.	Nomura et al., "Development of an Efficient Intermediate, α -[2-(Trimethylsilyl) ethoxy]-2-N-[2-trimethylsilyl]ethoxycarbonyl]folic Acid, for the Synthesis of Folate (γ)-Conjugates, and Its Application to the Synthesis of Folate-Nucleoside Conjugates," <u>J. Org. Chem.</u> 65:5016-5021 (2000)
377.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
*	Noviello et al., "Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid β Precursor Protein*," <u>The Journal of Biological Chemistry</u> , 278, 31843-31847 (2003)
378.	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <u>Nature Medicine</u> 8:7, 681-686 (2002)
*	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <u>Cell</u> 107:309-321 (2001)
379.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
*	Ohno-Matsui et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <u>Am. J. Pathology</u> , 160, 711-719 (2002)
380.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
381.	Okamoto et al., "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions," <u>Journal of General Virology</u> 72:2697-2704 (1991)
*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta</u> 1238:86-90 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
	*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
	*	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
	*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
	382.	Ozes et al., "A Comparison of Interferon-Con1 with Natural Recombinant Interferons- α : Antiviral, Antiproliferative, and Natural Killer-Inducing Activities," <i>Journal of Interferon Research</i> 12:55-59 (1992)
	*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localizatin in Drosophila Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)
	383.	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the RNase P and pre-tRNA," <i>Proc. Natl. Acad. Sci. USA</i> 92:12510-12514 (1995)
	*	Pandey et al., "Role ov B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	*	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
	384.	Pasquinelli et al., "Hepatitis C Virus Core and E2 Protein Expression in Transgenic Mice," <i>Hepatology</i> 25(3):719-727 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(Use several sheets if necessary)					
Applicant:				McSwiggen et al.			
Filing Date:		Group:		September 16, 2003		1632	

	*	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)
	385.	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature BiotechnologPy</i> 20:505-508 (2002)
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
	386.	Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis delta virus RNA," <i>Nature</i> 350:434-436 (1991)
	387.	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <i>Biochemistry</i> 31:16-21 (1992)
	388.	Pestka, "Interferon from 1981 to 1986," <i>Methods in Enzymology</i> , 119:3-15 (1986)
	389.	Pestka et al., "Interferons and Their Actions," <i>Ann. Rev. Biochem.</i> 56:727-777 (1987)
	*	Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System, <i>Bioconjugate Chem.</i> , 13, 845-854 (2002)
	390.	Pfeffer and Strulovici, "Transmembrane Secondary Messengers for IFN α/β <i>Interferon. Principles and Medical Applications</i> 151-160 (1992)
	391.	Pichlmayr et al., "Indications for Liver Transplantation in Heptobiliary Malignancy," <i>Hepatology</i> 20:33S-40S (1994)
	*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	*	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)
	392.	Pietschmann et al., "Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture," <i>Journal of Virology</i> , 40008-4021 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	393.	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 78:55-113 (1998)
	*	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)
	394.	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)
	395.	Preat et al., "Topical delivery of nucleic acids in skin," <i>S.T.P. Pharma Sciences</i> , 11(1) 57-68 (2001)
	396.	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:4253-4258 (1993)
	397.	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <i>Biochemistry</i> 33:2716-2725 (1994)
	*	Rajakumar et al., "Effects of Intrastriatal Infusion of D2 Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)
	*	Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," <i>PNAS</i> , 100, 235-240 (2003)
	398.	Regnier et al., "Parameters Controlling Topical Delivery of Oligonucleotides by Electroporation," <i>Journal of Drug Targeting</i> , 5(4), 275-289 (1998)
	*	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <i>Science</i> 297:1831 (2002)
	*	Reinhart et al., "MicroRNAs in Plants," <i>Genes & Development</i> 16:1616-1626 (2002)
	399.	Reynolds et al., "Rational siRNA design for RNA interference," <i>Nature Biotechnology</i> , 22, 3, 326-330 (2004) [also referred to as 1 February 4 2004, doi:10.1038/nbt936]
	*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

400.	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <u>J. Biol. Chem.</u> 247:5243-5251 (1972)
401.	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <u>Aids Research and Human Retroviruses</u> 8:183-189 (1992)
402.	Rubinstein, "Multiple Interferon Subtypes: The Phenomenon and Its Relevance," <u>Journal of Interferon Research</u> 7:545-551 (1987)
403.	Ruoslahti, "RGD and Other Recognition Sequences for Integrins," <u>Annu. Rev. Cell Dev. Biol.</u> 12:697-715 (1996)
*	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <u>Principles of Nucleic Acid Structure</u> 158-200 (1984)
404.	Salo et al., "Aminooxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support," <u>Bioconjugate Chem.</u> 10:815-823 (1999)
405.	Samuel, "The RNA-Dependent PI/eIF-2 α Protein Kinase," <i>Interferon: Principles & Medical Applications</i> pp237-249 (1992)
406.	Sanghvi et al., "Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator," <u>Organic Process Res. & Dev.</u> 4:175-181 (2000)
*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
407.	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," <u>Biochemistry</u> 37:13330-13342 (1998)
408.	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <u>J. Am. Chem. Soc.</u> 122:2433-2439 (2000)
409.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(Use several sheets if necessary)		
Applicant:				
McSwiggen et al.				
Filing Date:		Group:		
September 16, 2003		1632		

410.	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In <i>Neurospora</i> Mitochondria," <i>Cell</i> 61:685-696 (1990)
411.	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <i>Proc. Natl. Acad. Sci. USA</i> 88:8826-8830 (1991)
412.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <i>Proc. Natl. Acad. Sci. USA</i> 88:10591-10595 (1991)
*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl Acids Res.</i> 18:5433-5441 (1990)
413.	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <i>The Journal of Biological Chemistry</i> 274:21783-21789 (1999)
414.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
*	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 23:941-949, 1999]
*	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)
415.	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 1115, 199-208 (2003)
416.	Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," <i>Science</i> 285:1569-1572 (1999)
417.	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <i>Cell</i> 81:991-1002 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

	*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)
	*	Segarra et al., "Molecular characterization of the Enterococcus faecalis cytolysin activator," <i>Infection and Immunity</i> , 59, 4, 1239-1246 (1991) Database CAPLUS on STN, AN:1992:230597
	418.	Seipp et al., "Establishment of persistent hepatitis C virus infection and replication <i>in vitro</i> ," <u>Journal of General Virology</u> 78:2467-2476 (1997)
	*	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
	*	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
	*	Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
	*	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <u>Nucleic Acids Research</u> , 31 (14), 4109-4118 (2003)
	419.	Sherlock, "Viral hepatitis," <u>The Lancet</u> 339:802 (1992)
	*	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)
	420.	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
	421.	Silvestri et al., "CYP Enzyme Polymorphisms and Susceptibility to HCV-related Chronic Liver Disease and Liver Cancer," <i>Int. J. Cancer</i> , 104:310-317 (2003)
	*	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
	422.	Simmonds et al., "Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions," <u>Journal of General Virology</u> 75:1053-1061 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

	423.	Simmonds, "Variability of Hepatitis C Virus," <i>Hepatology</i> 21:570-583 (1995)
	424.	Smith and Simmonds, "Characteristics of Nucleotide Substitution in the Hepatitis C Virus Genome: Constraints on Sequence Change in Coding Regions at Both Ends of the Genome," <i>J. Mol. Evol.</i> 45:238-246 (1997)
	425.	Snyder et al., "Defining Genes in the Genomics Era," <i>Science</i> , 300, 258-260 (2003)
	*	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998)
	426.	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
	427.	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense & Nucleic Acid Drug Development</i> 7:151-157 (1997)
	*	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]
	428.	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," <i>Science</i> 249:73-75 (1990)
	429.	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <i>Biochemistry</i> 35:1201-1211 (1996)
	430.	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Reaction Site," <i>Science</i> 267:675-679 (1995)
	431.	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:619-622 (1994)
	432.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

433.	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <u>Cell</u> 63:601-608 (1990)
*	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc.," <u>Current Opinion in Molecular Therapeutics</u> 2:100-105 (2000)
434.	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in <u>The RNA World</u> , edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
*	Szostak, " <i>In Vitro</i> Genes," <u>TIBS</u> 17:89-93 (1993)
435.	Tagawa et al., "Infection of human hepatocyte cell lines with hepatitis C virus <i>in vitro</i> ," <u>Journal of Gastroenterology and Hepatology</u> 10:523-527 (1995)
*	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
*	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <u>Cancer Research</u> 54:4233-4237 (1994)
436.	Takahashi et al., "Natural Course of Chronic Hepatitis C," <u>The American Journal of Gastroenterology</u> 88(2):240-243 (1993)
437.	Takehara et al., "Expression of the Hepatitis C Virus Genome in Rat Liver After Cationic Liposome-Mediated <i>In Vivo</i> Gene Transfer," <u>Hepatology</u> 21:746-751 (1995)
*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <u>RNA</u> 3:914-925 (1997)
*	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <u>PNAS</u> , 99, 14640-14645 (2002)
438.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

439.	Tong et al., "Evidence for Hepatitis C Viral Infection in Patients With Primary Hepatocellular Carcinoma," <i>West J Med</i> 160:133-138 (1994)
440.	Tong et al., "Prediction of Response During Interferon Alfa 2b Therapy in Chronic Hepatitis C Patients Using Viral and Biochemical Characteristics: A Comparison," <i>Hepatology</i> 26(6):1640-1645 (1997)
441.	Tong et al., "Treatment of Chronic Hepatitis C With Consensus Interferon: A Multicenter, Randomized, Controlled Trial," <i>Hepatology</i> 26(3):747-754 (1997)
442.	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <i>Proc. Natl. Acad. Sci. USA</i> 90:1300-1304 (1993)
443.	Trinchet et al., "Carcinome Hépatocellulaire: Traitement par Chimioembolisation Artérielle," <i>Presse Med</i> 23(18):831-3 (1994)
*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> Volume LII, pp. 123-133 (1987)
*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
*	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
*	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999)
*	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
	Applicant: McSwiggen et al.	
	Filing Date: September 16, 2003	Group: 1632

444.	Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," <i>Nucleic Acids Research</i> , 32, 3, 936-948 (2004) [also referred to as doi:10.1093/nar/gkh247]
*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>TIBS</i> 17:334-339 (1992)
*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109:7845-7854 (1987)
*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <i>Nucleic Acids Symposium Series</i> 31:163-164 (1994)
445.	Usman et al., "Hammerhead ribozyme engineering," <i>Current Opinion in Structural Biology</i> 1:527-533(1996)
*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <i>Biochemistry</i> 36:6495-6501 (1997)
446.	Valli et al., "Detection of a 5' UTR variation in the HCV genome after long-term <i>in vitro</i> infection," <i>Institut Pasteur/Elsevier</i> 146:285-288 (1995)
*	Vassar et al., " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <i>Science</i> 286:735-741 (1999)
447.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <i>Nucleic Acids Research</i> 21:3249-3255 (1993)
*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <i>Science</i> , 303, 672-676 (2004)
*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
448.	Vogt et al., "Biology of the human hair follicle/New Insights and their clinical significance," <i>Der Hautarzt</i> , 54(8):692-698 (2003) ABSTRACT ONLY – ENGLISH

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632
(Use several sheets if necessary)			

	*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002)
	449.	Wang et al., "Delivery of Antisense Oligodeoxyribonucleotides Against the Human Epidermal Growth Factor Receptor into Cultured KB Cells with Liposomes Conjugated to Folate via Polyethylene Glycol," <u>Proc. Natl. Acad. Sci. USA</u> 92:3318-3322 (1995)
	450.	Wang et al., "Translation of Human Hepatitis C Virus RNA in Cultured Cells Is Mediated by an Internal Ribosome-Binding Mechanism," <u>Journal of Virology</u> 67(6):3338-3344 (1993)
	*	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> , 95, 13959-13964 (1998)
	451.	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <u>Journal of Virology</u> 65:5531-5534 (1994)
	452.	Wen et al., "Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome," <u>World J Gastroenterology</u> , 10(2):244-249 (2004)
	453.	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <u>Nucleic Acids Research</u> 23:2092-2096 (1995)
	*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
	*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
	*	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 16, 2003	Group: 1632

454.	Woolf et al., "Specificity of Antisense Oligonucleotides <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 89:7305-7309 (1992)
455.	Wraight et al., "Antisense oligonucleotides in cutaneous therapy," <u>Pharmacology & Therapeutics</u> , 90, 89-104 (2001)
456.	Wu and Kaufman, "A Model for the Double-stranded RNA (dsRNA)-dependent Dimerization and Activation of the dsRNA-activated Protein Kinase PKR*," <u>The Journal of Biological Chemistry</u> , 272:2, 1291-1296 (1997)
*	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <u>The Journ. of Biol. Chem.</u> 262:4429-4432 (1987)
*	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," <u>BioPharm</u> 32-38 (1999)
*	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <u>Nature Biology</u> , Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)
457.	Yamamoto et al., " <i>In Vivo</i> Transfection of Hepatitis C Virus Complementary DNA Into Rodent Liver by Asialoglycoprotein Receptor Mediated Gene Delivery," <u>Hepatology</u> 22(3):847-855 (1995)
*	Yan et al., "Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity," <u>Nature</u> 402:533-537 (1999)
*	Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," <u>PNAS</u> , 99, 21, 13825-13830 (2002)
458.	Yoo et al., "Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected with HCV," <u>Journal of Virology</u> 69(1):32-38 (1995)
459.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-763-B (400/129)	Serial No. 10/667,271
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: September 16, 2003	Group: 1632

	460.	Yuan et al., "Targeted cleavage of mRNA by human RNase P," <u>Proc. Natl. Acad. Sci. USA</u> 89:8006-8010 (1992)
	*	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
	461.	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <u>Nucleic Acids Research</u> 24:854-858 (1996)
	462.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
	*	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In Vivo</i> by a Change in GM3:GD3 Ganglioside Ratio," <u>Laboratory Investigation</u> 67:711-715 (1992)
	463.	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <u>Cell</u> 83:529-538 (1995)
	*	Zinnen et al., "Chemically Modified siRNAa: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.